You are here

  • Home
  • Archive
  • Volume 29, Issue Suppl 4
  • P87 Mesenchymal splice isoform fibroblast growth factor receptor (FGFR2c) is an independent prognostic biomarker and further refines risk stratification within endometrial cancer molecular subtypes

Article info

Article menu
Download PDFPDF
Poster exhibition Day 1
P87 Mesenchymal splice isoform fibroblast growth factor receptor (FGFR2c) is an independent prognostic biomarker and further refines risk stratification within endometrial cancer molecular subtypes

Authors

Citation

Sengal A, Williams E, McAlpine J, et al
P87 Mesenchymal splice isoform fibroblast growth factor receptor (FGFR2c) is an independent prognostic biomarker and further refines risk stratification within endometrial cancer molecular subtypes
International Journal of Gynecologic Cancer 2019;29:A107.

Publication history

  • First published November 1, 2019.
Online issue publication 
March 03, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.